Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Efficacy and safety of avandamet or uptitrated metformin treatment in patients with type 2 diabetes inadequately controlled with metformin alone: a multicenter, randomized, controlled trial.

Cai XL, Chen YL, Zhao JJ, Shan ZY, Qiu MC, Li CJ, Gu W, Tian HM, Yang HZ, Xue YM, Yang JK, Hong TP, Ji LN.

Chin Med J (Engl). 2015 May 20;128(10):1279-87. doi: 10.4103/0366-6999.156735.

2.

Sulfonylureas: Assets in the past, present and future.

Kalra S, Madhu SV, Bajaj S.

Indian J Endocrinol Metab. 2015 May-Jun;19(3):314-6. doi: 10.4103/2230-8210.149925. No abstract available.

3.

Diet is critical for prolonged glycemic control after short-term insulin treatment in high-fat diet-induced type 2 diabetic male mice.

Guo A, Daniels NA, Thuma J, McCall KD, Malgor R, Schwartz FL.

PLoS One. 2015 Jan 29;10(1):e0117556. doi: 10.1371/journal.pone.0117556. eCollection 2015.

4.

Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis.

Hemmingsen B, Schroll JB, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstrøm LH, Almdal T.

CMAJ Open. 2014 Jul 22;2(3):E162-75. doi: 10.9778/cmajo.20130073. eCollection 2014 Jul.

5.

Sex differences in type 2 diabetes: focus on disease course and outcomes.

Arnetz L, Ekberg NR, Alvarsson M.

Diabetes Metab Syndr Obes. 2014 Sep 16;7:409-20. doi: 10.2147/DMSO.S51301. eCollection 2014. Review.

6.

Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes.

Sreenan S, Andersen M, Thorsted BL, Wolden ML, Evans M.

Diabetes Ther. 2014 Dec;5(2):447-58. doi: 10.1007/s13300-014-0075-x. Epub 2014 Jul 15.

7.

Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective.

Harris SB, Khunti K, Landin-Olsson M, Galbo-Jørgensen CB, Bøgelund M, Chubb B, Gundgaard J, Evans M.

Patient Prefer Adherence. 2013 Sep 16;7:925-36. doi: 10.2147/PPA.S46805. eCollection 2013.

8.

In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.

Eldor R, DeFronzo RA, Abdul-Ghani M.

Diabetes Care. 2013 Aug;36 Suppl 2:S162-74. doi: 10.2337/dcS13-2003. Review. No abstract available.

9.

Influence of fibrinogen and C-RP on progression of peripheral arterial disease in type 2 diabetes: a preliminary report.

Bosevski M, Bosevska G, Stojanovska L.

Cardiovasc Diabetol. 2013 Feb 1;12:29. doi: 10.1186/1475-2840-12-29.

10.

Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis.

Sardone LD, Renlund R, Willett TL, Fantus IG, Grynpas MD.

Diabetes. 2011 Dec;60(12):3271-8. doi: 10.2337/db10-1672. Epub 2011 Oct 12.

11.

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.

Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Holman RR, Kahn SE; ADOPT Study Group.

Clin J Am Soc Nephrol. 2011 May;6(5):1032-40. doi: 10.2215/CJN.09291010. Epub 2011 Mar 31.

12.

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.

Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR; ADOPT Study Group.

Diabetes. 2011 May;60(5):1552-60. doi: 10.2337/db10-1392. Epub 2011 Mar 17.

13.
14.

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).

Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B; Diabetes Outcome Progression Trial (ADOPT) Study Group.

Diabetes Care. 2010 Jan;33(1):177-83. doi: 10.2337/dc09-1661. Epub 2009 Oct 6.

15.

The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions.

Gallwitz B.

Rev Diabet Stud. 2006 Winter;3(4):208-16. Epub 2007 Feb 10.

16.

Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial.

Glasziou P, Alexander J, Beller E, Clarke P; ADVANCE Collaborative Group.

Health Qual Life Outcomes. 2007 Apr 27;5:21.

17.

Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?

Heine RJ, Diamant M, Mbanya JC, Nathan DM.

BMJ. 2006 Dec 9;333(7580):1200-4. Review. No abstract available.

18.
Items per page

Supplemental Content

Write to the Help Desk